Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice

Clinical Cancer Research

Volumn 8, Issue 6, 2002, Pages 1932-1939

  Winding, Bent ^a   NicAmhlaoibh, Róisín ^a   Misander, Henriette ^a   Høegh Andersen, Pernille ^a   Andersen, Thomas Levin ^a   Holst Hansen, Claus ^b   Heegaard, Anne Marie ^a   Foged, Niels Tækker ^a   Brünner, Nils ^b   Delaissé, Jean Marie ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; ILOMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL INTERACTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; SCORING SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL SURVIVAL; DIPEPTIDES; FEMALE; GENE THERAPY; HUMANS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; OSTEOLYSIS; PHENYLALANINE; PROTEASE INHIBITORS; THIOPHENES; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0036281728     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Bone disease and malignancy
2. Pathogenesis of bone metastases: Role of tumor-related proteins
3. Matrix metalloproteinases: Multifunctional contributors to tumor progression
4. The bone lining cell: Its role in cleaning Howship's lacunae and initiating bone formation
5. Determination of bone markers in pycnodysostosis: Effects of cathepsin K deficiency on bone matrix degradation
6. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone
7. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts
8. Identification of matrix metalloproteinase 9 in rabbit osteoclasts
9. Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B
10. Distribution of matrix metalloproteinases and their inhibitor, TIMP-1, in developing human osteophytic bone
11. Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts
12. Proteinases in bone resorption: Obvious and less obvious roles
13. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose
14. Cell surface-localized matrix metallo-proteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis
15. Degradation of decorin by matrix metalloproteinases: Identification of the cleavage sites, kinetic analyses and transforming growth factor-β1 release
16. Molecular mechanisms of osteolytic bone metastases
17. Transforming growth factor-β-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway
18. Osteolytic bone metastasis in breast cancer
19. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
20. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones
21. Effects of parathyroid hormone (PTH) and PTH-related peptide on expressions of matrix metalloproteinase-2, -3, and -9 in growth plate chondrocyte cultures
22. Differential effects of transforming growth factor-β on the expression of collagenase-I and collagenase-3 in human fibroblasts
23. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation
24. Transforming growth factor β1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells
25. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
26. A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice
27. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model
28. Matrix metalloproteinase inhibition: A review of anti-tumour activity
29. Low molecular weight inhibitors in corneal ulceration
30. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones
31. Human breast cancer cells induced angiogenesis, recruitment, and activation of osteoclasts in osteolytic metastasis
32. lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis
33. A murine model of experimental metastasis to bone and bone marrow
34. Direct and indirect radiation effects on osteoclast formation in vitro
35. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer
36. A new synthetic inhibitor of mammalian tissue collagenase inhibits bone resorption in culture
37. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis
38. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model
39. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption
40. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
41. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells
42. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis
43. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice
44. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice
45. Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone micro-environment
46. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
47. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma